NCT05120648

Brief Summary

Biofeedback is a therapeutic paradigm that teaches patients how to gain awareness and control over previously unrecognized sympathetic changes such as body temperature, blood pressure, and heart rate. We propose to use a six session biofeedback protocol that includes heart-rate variability (HRV) biofeedback, respiration/relaxation training, and body temperature control to treat UCLA patients with chronic medical conditions (e.g. pulmonary, neurology) and somatic symptoms (pain, psychosomatic non-epileptic seizures, panic attacks, long-COVID symptoms). The aim of the study is to determine whether patients who complete a six-session biofeedback protocol report a decrease in somatic symptoms, and improvements in self-rated mental health (depression, anxiety, quality of life) after the program and at three-months follow-up. The investigators will also study whether these improvements are also related to reduced healthcare utilization.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2021

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

September 13, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 15, 2021

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

October 3, 2024

Status Verified

October 1, 2024

Enrollment Period

3 years

First QC Date

September 13, 2021

Last Update Submit

October 2, 2024

Conditions

Outcome Measures

Primary Outcomes (7)

  • Change in depression score on the PHQ-9

    Improvement in self-rated depressive sx on the PHQ-9

    3 months and 6 months

  • Change in quality of life (QOL)

    Improvement in self-rated QOL on the SF-36

    3 months and 6 months

  • Change in anxiety

    Improvement in self-rated anxiety sx on the GAD-7

    3 months and 6 months

  • Reduced physical symptoms

    Improvement in self-rated physical symptoms on the PHQ-15

    3 months and 6 months

  • Improved self-efficacy

    Improvement in self-rated self-efficacy on the Self-efficacy for Managing Chronic Disease 6-item Scale

    3 months and 6 months

  • Reduced health anxiety

    Reduced scores on the self-reported Health Anxiety Inventory

    3 months and 6 months

  • Improved sleep

    Improved sleep and reduced insomnia on the PSQI

    3 months and 6 months

Secondary Outcomes (1)

  • Reduced healthcare utilization

    3 months and 6 months

Study Arms (2)

Immediate enrollment

Behavioral: Biofeedback

Wait-list controls

Behavioral: Biofeedback

Interventions

BiofeedbackBEHAVIORAL

We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.

Immediate enrollmentWait-list controls

Eligibility Criteria

Age15 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

(1) participants must be between 15-60; (2) English speaking; (3) minor participants must have one parent consent to research and treatment; (4) participants must have at least one qualifying somatic complaint (seizure-like spells, pain, nausea) or have psychosocial distress related to the management of their medical conditions (comorbid panic attacks, low mood, etc.).

You may qualify if:

  • between 15-60 years of age
  • English speaking
  • minor participants must have one parent consent to research and treatment
  • must have at least one qualifying somatic complaint (seizure-like spells, pain, nausea) or have psychosocial distress related to the management of their medical conditions (comorbid panic attacks, low mood, etc.).

You may not qualify if:

  • severe psychopathology (e.g., psychosis, active suicidality, moderate to severe intellectual impairment).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCLA

Los Angeles, California, 90095, United States

Location

Related Publications (1)

  • Emerson ND, Lavretsky H, Pittman WQ, Viswanathan N, Siddarth P. An open trial of biofeedback for long COVID. J Psychosom Res. 2024 Apr;179:111625. doi: 10.1016/j.jpsychores.2024.111625. Epub 2024 Feb 23.

MeSH Terms

Conditions

Medically Unexplained Symptoms

Interventions

Biofeedback, Psychology

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Mind-Body TherapiesComplementary TherapiesTherapeuticsBehavior TherapyPsychotherapyBehavioral Disciplines and ActivitiesFeedback, Psychological

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Clinical Professor

Study Record Dates

First Submitted

September 13, 2021

First Posted

November 15, 2021

Study Start

September 1, 2021

Primary Completion

September 1, 2024

Study Completion

September 1, 2024

Last Updated

October 3, 2024

Record last verified: 2024-10

Locations